Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
NCT ID: NCT03649581
Last Updated: 2025-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
84 participants
INTERVENTIONAL
2019-02-28
2027-02-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We think that identifying subforms of psychotic disorders that are more homogeneous will better enable to understand their respective physiopathological causes and find personalized treatments.
This study will compare two subforms of psychotic disorders that have been clinically distinguished in the 1970s. These phenotypes have however not been validated yet using scientific investigations.
Using clinical assessments, cognitive evaluations and neurophysiological measures (fMRI) investigating the domains of affect and psychomotoricity , we expect that these two subforms will differ on their clinical, cognitive and neurophysiological characteristics, namely: hebephrenia will be associated with deficits on the affect markers , and respect psychomotoricity (catatonia scales, tests assessing movement planification) whereas the opposite pattern will be observed for periodic catatonia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia
NCT01295411
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
NCT03790085
Pain and Schizophrenia
NCT01244542
Sustained Attention Abilities in Schizophrenia
NCT02388607
Assessment of Schizophrenia Patients' Clinical Study Experiences
NCT05948111
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patient with schizophrenia and periodic catatonia
compare the two groups of schizophrenic patients
Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:
1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),
2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).
compare the two groups of schizophrenic patients versus volunteers
compare the results of the schizophrenic patient group with healthy volunteers
patient with schizophrenia and hebephrenia
compare the two groups of schizophrenic patients
Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:
1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),
2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).
compare the two groups of schizophrenic patients versus volunteers
compare the results of the schizophrenic patient group with healthy volunteers
healthy volunteers
compare the two groups of schizophrenic patients
Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:
1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),
2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).
compare the two groups of schizophrenic patients versus volunteers
compare the results of the schizophrenic patient group with healthy volunteers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
compare the two groups of schizophrenic patients
Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:
1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),
2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).
compare the two groups of schizophrenic patients versus volunteers
compare the results of the schizophrenic patient group with healthy volunteers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* male or female willing to participate and who have signed up the legal document
* under the protection of health insurance for patients only
* schizophrenia or schizo-affective disorder according to the DSM-5 criteria
* periodic catatonia or hebephrenia accordin to WKL classification
* clinically stable for at least 2 months
* in or out patients for controls only
* no psychiatric history
Exclusion Criteria
* current severe or unstable somatic illness
* neurological history (epilepsia, brain injury, brain surgery…)
* current substance use disorder (DSM-5)
* current major depressive disorder (DSM-5)
* mental retardation (IQ \< 70)
* pregnancy, breast feeding
* current legal control
* contra-indication for fMRI for controls only psychotropic intake during the last 3 weeks
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Psychiatrie I, Hôpital Civil, Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.